Novartis to spin off generics business Sandoz next year

* Co has not received formal offers for Sandoz to date

* Announcement of spin-off not a surprise - analysts

* Novartis shares inch lower in afternoon trading

By Natalie Grover

ZURICH/LONDON, Aug 25 (Reuters) - Novartis NOVN.S plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday, acknowledging it had not received any formal offers for the business to date.

The company started a strategic review of Sandoz last October - examining a range of options, including retaining the business, spinning it off or selling it - following a protracted period of underperformance driven largely by mounting pricing pressures in the off-patent drug sector.

Apart from some preliminary interest, Novartis has not received any formal binding offers for Sandoz so far - but if any "highly attractive" bids did emerge Novartis would fully consider them, CEO Vas Narasimhan said in a conference call with analysts.

However, "we think a spin is by far and away the most likely and best way to separate these two companies," he said.

The spin-off announcement did not come as a surprise given poor market conditions and the struggling broader market for generics, analysts said.

"Previous spin-outs from pharma company have created near-term excitement given the strong track record of pharma spins outperforming parents. In this case, the competitive pressures in the generic space are likely to translate into lesser near term interest," Citi analysts wrote in a note.

Novartis shares already appropriately reflect the valuation of the two businesses, added J.P. Morgan analysts in a note.

The Basel-based company's stock inched lower in afternoon trading.

Sandoz - which generated nearly $10 billion in sales last year selling generics and biosimilars (cheap versions of biologic drugs made from living organisms) - will emerge as Europe's leading generics company, according to Novartis.

Narasimhan described the market for generics as "highly attractive" going forward, citing $400 billion to $500 billion worth of branded products expected to go off-patent over the coming decade.

The standalone Sandoz is expected to be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt programme in the United States. Richard Saynor would remain CEO following the spin-off.

The transaction, which is anticipated to be generally tax-neutral for Novartis, is expected to be completed in the second half of next year, subject to market conditions, tax rulings and opinions, final board endorsement and shareholder approvals, Novartis said.

Plans for the spin-off would not be derailed by U.S. drug pricing reforms, Narasimhan said.

Last week, a landmark law that included provisions to tackle the rising cost of medicines was passed in the United States, in a rare legislative defeat for the powerful pharmaceutical industry.

Sandoz will, however, reassess whether certain biosimilars still are an attractive market opportunity, added Narasimhan.


Sandoz's sales have been hurt by pricing pressure that has affected the broader generics industry for years, particularly in the United States, although the country accounts for less than a quarter of its total sales.

In 2021, sales in Europe declined by 2%, while U.S. sales tumbled 15% on a constant currency basis, hit also by a COVID-related drop in demand.

However, there are encouraging signs. Last month, Novartis said Sandoz's earnings would likely hold steady this year, primarily thanks to growth in Europe.

Narasimhan also predicted a return to U.S. growth, with expected biosimilar approvals for blockbuster medicines such as Humira and Tysabri next year.

Novartis has been pruning its business interests, spinning off its Alcon eye care business in 2019 and last November agreeing to sell a nearly one-third voting stake in Roche ROG.S .

It tried to divest part of Sandoz back in 2018, but a $900 million deal with India’s Aurobindo Pharma ARBN.NS fell foul of antitrust rules.

Now, Narasimhan is aiming to spin off the entire division, which accounted for close to a fifth of Novartis’ $51.6 billion in sales last year.

Novartis is also implementing a restructuring programme that involves cutting up to 8,000 jobs, or about 7.4% of its global workforce.

Reporting by Silke Koltrowitz and Natalie Grover Editing by Mark Potter and Elaine Hardcastle

Mga Kaugnay na Asset

Pinakabagong Balita

Oil bounces on pipeline shutdown, but heads for weekly loss on demand woes


Asian currencies get lift from tempered Fed rate view


African Markets - Factors to watch on

Truckers' union in South Korea ends strike - vote

India stocks, rupee, swaps, call at 10 a.m. IST

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.